Speaker Profile
Ph.D., CEO, MKC Biotherapeutics
Biography
Successful Biotechnology Executive with private public company experiences in the field of Cell Gene Therapies and ATMP products over the past 3+ decades. The most recent 2+ decades as C-level executive with responsibilities for development of therapeutic products and technology platforms from concept through commercialization FDA approvals. Multiple successful start-up experiences including technology, business, licensing, operations fund-raising financing responsibilities. Operational management (including PL) responsibilities with private and public companies including management of pharmaceutical partner relationships in US Asian territories. Inducted into College of Fellows of the American Institute of Medical and Biological Engineers (AIMBE) for contributions to the development of the field of Cell Gene Therapy.
Talk
Cell-based Therapeutic with Clinical Efficacy with Functional Tissue Regeneration
Our initial product portfolio is based on in-licensing IP Technology encompassing robust scalable pooled allogeneic bone-marrow Mesenchymal Stromal Cell (MSC) platform (NatureSciReports 14:12654, June2024). This platform has resulted in commercial marketing of Products for three indications in India. We will describe data (AmJSportsMed 51:2254 July2023) and plans for pivotal trials for knee osteoarthritis in USEurope.
Emerging Therapeutics Showcase:
MKC Biotherapeutics, Inc.
MKC Biotherapeutics business model to identify and in-license novel therapeutic platforms / product assets with demonstrated human safety & efficacy data with durable clinical benefit (ideally, commercially marketed in select countries outside US/Europe under country-specific-FDA approval) and undertake clinical / regulatory development for commercial markets in US/Europe.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
